DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment (NCT07158164)
🩺 Plain-English Summary (8th-Grade Level)
To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm.
Who can join: Review the eligibility criteria below.
Location: RWJBarnabas Health Clara Maas Medical Center — Belleville, New Jersey
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- RWJBarnabas Health Clara Maas Medical Center — Belleville, New Jersey
- Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton — Hamilton, New Jersey
- RWJBarnabas Health Jersey City Medical Center — Jersey City, New Jersey
- Cooperman Barnabas Medical Center — Livingston, New Jersey
- Jack and Sheryl Morris Cancer Center — New Brunswick, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospita — New Brunswick, New Jersey
- Cancer Center Initiative — Newark, New Jersey
- University Hospital — Newark, New Jersey
- RWJBarnabas Health Newark Beth Israel Medical Center — Newark, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital Somerset — Somerville, New Jersey
- RWJBarnabas Health - Community Medical Center — Toms River, New Jersey
📞 Contact the Study Coordinator
Phone: (732) 253-5618
Email: howard.hochster@rutgers.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Neoplasms
- S0820, Adenoma and Second Primary Prevention Trial — Birmingham, Alabama
- MyGI Diet for Colorectal Cancer Prevention — Ann Arbor, Michigan
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer — Gilbert, Arizona
- Combination Immunotherapy in Colorectal Cancer — Brooklyn, New York
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors — Encinitas, California
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... — Bethesda, Maryland
Explore by condition: All Colorectal Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.